Kostas N. Botsoglou, MD

Medical experts engage in a discussion surrounding the treatment and management of patients diagnosed with psoriasis and psoriatic arthritis.

Dermatologic experts explore strategies to slow the progression of psoriasis to psoriatic arthritis, offering evidence-based insights to optimize patient outcomes and enhance long-term disease management.

Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.

Providers in inflammatory diseases discuss the instrumental role nurses and support staff play in educating patients on adalimumab biosimilars.

Drs Lio, Botsoglou, and Alexrad discuss the most asked questions and common concerns patients have on adalimumab biosimilars.

Clinicians and a pharmacist discuss how they are managing access and assistance with copay assistance program in their practices.

Healthcare providers in inflammatory diseases talk about the role they have on encouraging adalimumab biosimilar use in clinical practice.

Specialists in rheumatology, dermatology and gastrointestinal disease share their clinical experience on initiating or switching their patients on adalimumab biosimilars.

Specialists in rheumatology, dermatology and gastrointestinal disease discuss the evidence on efficacy and safety on switching patient to an adalimumab biosimilar.

Providers in rheumatology, dermatology and gastrointestinal disease talk about how they are selecting between the various adalimumab biosimilars available for their patients.

A clinical pharmacist and specialists in rheumatology, dermatology, and gastrointestinal disease share strategies in how to increase the uptake of adalimumab biosimilar among providers.

A clinical pharmacist discusses the role of pharmacy benefit managers and payers in accessibility of adalimumab biosimilars.

Experts talk about the impact of the launch of adalimumab biosimilar on their clinical practices and pharmacy.

Specialists in rheumatology, dermatology and gastrointestinal disease discuss clinical trials that have shown safety and efficacy of adalimumab biosimilars in inflammatory diseases.

A clinical pharmacist reviews the various pharmacological aspects of the available adalimumab biosimilars.

Clinicians and a pharmacist provide an overview of the emerging adalimumab biosimilars in the recent years.

Drs Lio, Botsoglou, and Axelrad discuss the need for biosimilars in inflammatory diseases, and clinical pharmacist Dr Humphreys reviews the regulatory requirements for biosimilars to receive FDA approval.

Experts conclude their discussion emphasizing the importance of integrative care and how providers can improve outcomes for their patients with fibromyalgia (FM).

Experts highlight current challenges in their practice treating patients with fibromyalgia (FM).

Experts discuss how they personalize treatments for patients with fibromyalgia (FM) and the importance of improving sleep in their approach.

Experts discuss the limited combination therapy options for the treatment of fibromyalgia (FM) and how to inform patients of prospective outcomes.

Experts discuss their step therapy approaches for the treatment of fibromyalgia (FM).

Experts discuss the long-term safety and efficacy of agents used for the treatment of fibromyalgia (FM).

Experts discuss the FDA approved agents duloxetine and pregabalin for the treatment of fibromyalgia (FM).

Experts discuss the FDA approved agent milnacipran for the treatment of fibromyalgia (FM).

Experts offer their clinical experience discussing how they utilize off label drugs in the treatment of fibromyalgia (FM).

Experts offer their clinical experience with nonsteroidal anti-inflammatory drugs (NSAID) in the treatment of fibromyalgia (FM).

Experts discuss their therapeutic approach and key agents utilized in the treatment of fibromyalgia (FM).

Experts discuss treatment options for fibromyalgia (FM) and how they utilize integrative care with patients.

Experts discuss which providers often diagnose fibromyalgia (FM) and how the burden of care has changed in recent years.